

Defined hydrogel enables reproducible culture of cancer cells in xenograft models.

AMSBIO has launched **MatriMix for PDX**, a fully defined extracellular matrix (ECM) hydrogel comprising of collagen, laminin-511 E8 fragments and hyaluronic acid optimized to support **patient-derived xenograft (PDX)** studies.




Image captions: A: Vascular formation in tumor tissue cultured in MatriMix for PDX (endothelial cell marker, purple).

A PDX model

uses a patient's tumor tissue to create a growing tumor in an immunodeficient mouse. They retain the histological and genetic characteristics of the patient's original tumor, offering a superior platform for studying cancer biology and drug responses, allowing researchers to develop new treatments through drug screening and toxicology studies.

Comprising a mixture of fully defined collagen type I, I

aminin-511 E8 fragments, and hyaluronic acid, MatriMix for PDX is a ready-to-use 3D culture substrate product optimized for culturing patient derived cancer cells. Proven to facilitate excellent cell organization and accurately replicate in vivo conditions, MatriMix for PDX is the ultimate solution for culturing even difficult-to-grow cancer cell types as xenograft. The high lot-to-lot consistency of MatriMix for PDX enables researchers to routinely obtain highly reproducible results.




Image captions: B: Proliferation of transplanted colorectal cancer cells (red), stroma tissue (green) and cell nuclei (blue) in MatriMix for PDX

The types and concentrations

of the individual components in MatriMix for PDX have been optimized to provide an optimal extracellular environment for target cells. Through its use of medical grade porcine collagens, MatriMix for PDX streamlines the transition from basic to clinical research unlike any existing natural hydrogel.

Supplied frozen, MatriMix

for PDX transitions to a clear gel when warmed to physiological temperature (37⁰C). This feature allows superior visualization possibilities, making it valuable for applications requiring real-time monitoring of tumor growth, invasion, and drug response assays. MatriMix for PDX comes as a single, all-in-one vial. MatriMix is also available in a tunable three-vial format, allowing end-users to optimize for their specific 3D Cell Culture or organoid models.

For further information

on MatriMix for PDX please visit <https://www.amsbio.com/3d-cell-culture-extracellular-matrices/matrimix> or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.



Now part of the Europa Biosite group

of companies, AMS Biotechnology (AMSBIO) is recognized as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.

Worldwide HQ

AMS Biotechnology (AMSBIO)

184 Milton Park
Abingdon
Oxon OX14 4SE
UK

Tel: +44-1235-828200

Fax: +44-1235-820482

Email: info@amsbio.com

Web www.amsbio.com